PD-1

January 18, 2019

Tyvyt, PD-1 Inhibitor Newly Approved in China, Showed Efficacy Similar to Opdivo and Keytruda, Trial Data Show

News

The immune checkpoint inhibitor Tyvyt (sintilimab injection) reduced tumor burden in eight out of 10 people with relapsed or refractory classic Hodgkin’s lymphoma taking part in a Phase 2 clinical ... Read more

January 8, 2019

Tyvyt Approved in China for Previously Treated Classical Hodgkin’s Lymphoma

News

Tyvyt (sintilimab injection), an immune checkpoint inhibitor jointly developed by Innovent Biologics and Eli Lilly and Company in China, is now available as a therapy for patients with classical Hodgkin’s lymphoma who failed to respond ... Read more

July 9, 2018

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

News

Sintilimab (IBI308), an immunotherapy candidate, was found to be safe and completely eliminated tumors in one-fourth of Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) treated in a Phase 2 ... Read more

December 20, 2017December 20, 2017

Key Genes in T-cell Lymphoma Patients Often Missing Agent That Blocks Cancer Signaling, Study Says

News

The tumor suppressor PD-1, which serves as shut-off switch to prevent damaged T-cells from continuing to develop and proliferate, is frequently missing in crucial genes of patients with T-cell lymphomas, a ... Read more

January 26, 2016January 26, 2016

New Hodgkin Lymphoma Combo Therapy of Keytruda and AFM13 to Move into Clinical Trial

News

Affimed Therapeutics N.V. , a German clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reports that it has entered into an immuno-oncology clinical research collaboration with ... Read more

November 24, 2015November 24, 2015

Immune Checkpoint Inhibitors in Hodgkin’s Lymphoma Highlighted in New Article

News

Hodgkin’s lymphoma (HL) is a cancer of the immune system where malignant Hodgkin Reed-Sternberg cells are present among immune cells, such as T cells, and use different immunosuppressive mechanisms to evade ... Read more